A novel regimen of vorinostat with interferon gamma for refractory Sezary syndrome.

Author(s): Gardner JM, Introcaso CE, Nasta SD, Kim EJ, Vittorio CC, Rook AH

Affiliation(s): Department of Dermatology, Hospital of the University of Pennsylvania, 3600 Spruce Street, Philadelphia, PA 19146, USA.

Publication date & source: 2009-07, J Am Acad Dermatol., 61(1):112-6.

Publication type: Case Reports

Long-term prognosis for advanced stages of cutaneous T-cell lymphoma may be beneficially altered with the use of multimodality therapy. However, refractory disease exists in which current therapeutic options fail to halt the progression of disease. We present 3 cases of refractory Sezary syndrome in which the combination of vorinostat and interferon gamma was well tolerated and produced significant clinical improvement. The potential immunologic basis for this is discussed.